Distribuzione geografica
Continente #
NA - Nord America 286
EU - Europa 203
AS - Asia 11
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 503
Nazione #
US - Stati Uniti d'America 284
IT - Italia 116
SE - Svezia 43
GB - Regno Unito 9
DE - Germania 8
IE - Irlanda 6
IN - India 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
FR - Francia 3
GR - Grecia 3
RU - Federazione Russa 3
CA - Canada 2
HK - Hong Kong 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
CM - Camerun 1
EC - Ecuador 1
FI - Finlandia 1
IL - Israele 1
KR - Corea 1
NL - Olanda 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
Totale 503
Città #
Rome 78
Santa Cruz 56
Stockholm 42
Fairfield 20
Woodbridge 15
Seattle 13
Buffalo 10
Cambridge 10
Houston 9
Ashburn 8
Milan 8
San Diego 8
Dublin 6
Ann Arbor 5
Esslingen am Neckar 4
Wilmington 4
Athens 3
Atlanta 3
Fleming Island 3
Florence 3
London 3
Los Angeles 3
Provo 3
Saint Petersburg 3
Auburn 2
Central 2
Chicago 2
Dulles 2
Duncan 2
Gillingham 2
Hanwell 2
Lake Forest 2
Las Vegas 2
Lausanne 2
Lissone 2
Palo Alto 2
Reggio Emilia 2
Rivolta d'Adda 2
San Francisco 2
Torino 2
Ahmedabad 1
Altamura 1
Arezzo 1
Asti 1
Boardman 1
Boiling Springs 1
Brooklyn 1
Casarile 1
Cebu City 1
Chandler 1
Cheyenne 1
Clearwater 1
Council Bluffs 1
Dallas 1
Denver 1
Douala 1
Foggia 1
Francavilla Fontana 1
Gurgaon 1
Guymon 1
Honolulu 1
Iesi 1
Indiana 1
Lehmo 1
Manduria 1
Miami 1
Modugno 1
Mumbai 1
Naples 1
New York 1
Nîmes 1
Orleans 1
Ponte nelle Alpi 1
Porto 1
Prague 1
Quito 1
Red Deer 1
Seoul 1
Siena 1
Solihull 1
South Bend 1
Southend 1
Tel Aviv 1
Terracina 1
Trecate 1
Vijayawada 1
Yellow Springs 1
Totale 399
Nome #
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations, file e291c0d9-d4d5-cddb-e053-3a05fe0aa144 79
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy, file e291c0d9-ba99-cddb-e053-3a05fe0aa144 67
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study., file e291c0d7-180d-cddb-e053-3a05fe0aa144 65
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?, file e291c0d9-026f-cddb-e053-3a05fe0aa144 56
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study, file e291c0d9-7daa-cddb-e053-3a05fe0aa144 47
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents, file e291c0d9-d6b8-cddb-e053-3a05fe0aa144 46
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study, file e291c0d8-938a-cddb-e053-3a05fe0aa144 43
Quality of life and psychological impact in patients with atopic dermatitis, file e291c0d9-bddd-cddb-e053-3a05fe0aa144 31
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab, file e291c0d8-bc57-cddb-e053-3a05fe0aa144 14
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study., file e291c0d9-1ef6-cddb-e053-3a05fe0aa144 13
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients., file e291c0d6-bf7c-cddb-e053-3a05fe0aa144 4
null, file 03272474-2f6b-43c6-9ca7-102e32fb8240 3
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy, file e291c0d7-7ca2-cddb-e053-3a05fe0aa144 3
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up, file e291c0d8-bc54-cddb-e053-3a05fe0aa144 3
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients., file e291c0d6-b1f0-cddb-e053-3a05fe0aa144 2
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies, file e291c0d6-d43e-cddb-e053-3a05fe0aa144 2
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation, file e291c0d7-11d8-cddb-e053-3a05fe0aa144 2
Skin immunity and its dysregulation in psoriasis, file e291c0d7-d665-cddb-e053-3a05fe0aa144 2
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study, file e291c0d7-f491-cddb-e053-3a05fe0aa144 2
Pharmacotherapeutic management of psoriasis in adolescents and children, file e291c0d8-1341-cddb-e053-3a05fe0aa144 2
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis, file e291c0d8-ba82-cddb-e053-3a05fe0aa144 2
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab, file e291c0d8-d400-cddb-e053-3a05fe0aa144 2
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study., file e291c0d8-eb64-cddb-e053-3a05fe0aa144 2
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience, file e291c0d8-ef04-cddb-e053-3a05fe0aa144 2
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies, file e291c0d8-f27b-cddb-e053-3a05fe0aa144 2
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy, file c84625a9-a789-49ac-aaa0-3464efa3321b 1
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice, file e291c0d5-4696-cddb-e053-3a05fe0aa144 1
Tildrakizumab for treating psoriasis, file e291c0d6-ad19-cddb-e053-3a05fe0aa144 1
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature, file e291c0d6-b226-cddb-e053-3a05fe0aa144 1
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients, file e291c0d6-da20-cddb-e053-3a05fe0aa144 1
Photo-recall cutaneous reaction to gemcitabine, file e291c0d6-dbbd-cddb-e053-3a05fe0aa144 1
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy, file e291c0d7-15ee-cddb-e053-3a05fe0aa144 1
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab, file e291c0d7-2000-cddb-e053-3a05fe0aa144 1
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial, file e291c0d7-3538-cddb-e053-3a05fe0aa144 1
Successful treatment of psoriatic crumbly nails with ustekinumab, file e291c0d7-791b-cddb-e053-3a05fe0aa144 1
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date, file e291c0d7-84c9-cddb-e053-3a05fe0aa144 1
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab, file e291c0d7-b9e8-cddb-e053-3a05fe0aa144 1
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab, file e291c0d7-d65f-cddb-e053-3a05fe0aa144 1
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature, file e291c0d7-d661-cddb-e053-3a05fe0aa144 1
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris, file e291c0d8-9787-cddb-e053-3a05fe0aa144 1
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts, file e291c0d8-9793-cddb-e053-3a05fe0aa144 1
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy, file e291c0d8-b59b-cddb-e053-3a05fe0aa144 1
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo, file e291c0d8-ba7c-cddb-e053-3a05fe0aa144 1
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study, file e291c0d8-bc46-cddb-e053-3a05fe0aa144 1
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases, file e291c0d8-bc50-cddb-e053-3a05fe0aa144 1
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis, file e291c0d8-bc52-cddb-e053-3a05fe0aa144 1
Linear psoriasis following the typical distribution of the sciatic nerve, file e291c0d8-bc58-cddb-e053-3a05fe0aa144 1
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis, file e291c0d8-cf07-cddb-e053-3a05fe0aa144 1
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature, file e291c0d8-d377-cddb-e053-3a05fe0aa144 1
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study, file e291c0d8-d385-cddb-e053-3a05fe0aa144 1
Italian guidelines in diagnosis and treatment of alopecia areata, file e291c0d8-e157-cddb-e053-3a05fe0aa144 1
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome, file e291c0d8-eb66-cddb-e053-3a05fe0aa144 1
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis, file e291c0d8-eb6a-cddb-e053-3a05fe0aa144 1
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab, file e291c0d8-eec4-cddb-e053-3a05fe0aa144 1
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis, file e291c0d8-eec9-cddb-e053-3a05fe0aa144 1
Totale 526
Categoria #
all - tutte 997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 997

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021126 0008 675 24 91966
2021/2022177 0210 63 1418 15147529
2022/2023223 575825 1132 3013 1314141
Totale 526